One in Three Rheumatologists View BMS' Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Exton, PA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- With the FDA's March 6, 2026 PDUFA date approaching for Sotyktu (deucravacitinib) in psoriatic arthritis (PsA), new findings from RealTime Dynamix™: Psoriatic Arthritis Q1 (US), show that U.S. rheumatologists are actively monitoring the potential approval. Sotyktu, an oral selective TYK2 inhibitor currently approved in psoriasis, is under FDA review for the treatment of adults with active psoriatic arthritis. Fielded among 104 U.S. rheumatologists in January 2026, the study indicates that nearly half are already aware of the upcoming FDA decision. Unaided, Sotyktu is the most frequently cited pipeline therapy in PsA, reflecting strong pre-launch visibility ahead of potential commercialization. Perceptions of differentiation are beginning to take shape, with one in three rheumatologists considering deucravacitinib a substantial advance over currently available PsA therapies. If approved, physicians estimate that roughly one-fifth of the
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer Obesity Nod In China And Cancer Wins Reframe Long Term Growth [Yahoo! Finance]Yahoo! Finance
- Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit [Yahoo! Finance]Yahoo! Finance
- Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate [Yahoo! Finance]Yahoo! Finance
- A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge [Yahoo! Finance]Yahoo! Finance
- Pfizer: Obesity Hype And Vaccine Policy Shocks [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- PFE's page on the SEC website